Navigation Links
Review finds conflicts of interest in many cancer studies
Date:5/10/2009

A new analysis finds that a considerable number of clinical cancer studies published in respected medical journals have financial connections to pharmaceutical companies. Published in the June 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that conflicts of interest may cause some researchers to report biased results that are favorable to companies.

Ties between clinical researchers and companies that make medical devices and drugs have become increasingly complex and controversial, particularly as more researchers compete for scarce federal research funds. In addition to using industry money to support their research, some investigators receive consulting fees, own stock and hold positions within companies that profit from selling the very products they are investigating. These conflicts of interest have raised concerns that studies with ties to industry are biased and are not designed to provide a true test of medical therapies. Many medical journals now require researchers to disclose potential conflicts of interest in the articles they submit for publication.

To get sense of the frequency and impact of conflicts of interest in clinical cancer research, Dr. Reshma Jagsi of the University of Michigan and colleagues reviewed cancer studies appearing in eight highly regarded journals in 2006. These journals included the New England Journal of Medicine; JAMA; the Lancet; the Journal of Clinical Oncology; the Journal of the National Cancer Institute; Lancet Oncology; Clinical Cancer Research; and CANCER.

Of the 1,534 cancer studies identified in these journals, 29 percent had conflicts of interest that were apparent from review of published author declarations and authorship lists (including industry funding, consulting fees to authors, co-authorship by industry employees, etc.), and 17 percent declared industry funding. Conflicts of interest were most often found in articles with primary authors from departments in medical oncology (45 percent), those from North America (33 percent), and those with male first and senior authors (37 percent).

According to the authors, randomized clinical trials that assessed patient survival were more likely to report a survival advantage associated with the intervention when a conflict of interest was present. These trials are the foundation by which drugs, technologies, diagnostic tests, etc. get approved for use in the clinic and therefore shape the way oncologists practice medicine.

The findings also show that studies with industry funding were more likely to focus on treatment than studies without industry funding (62 percent vs. 36 percent). They were less likely than studies not declaring industry funding to focus on epidemiology, prevention, risk factors, screening or diagnostic methods (20 percent vs. 47 percent).

This analysis revealed that conflicts of interest exist in a considerable number of clinical cancer research articles published in important journals. The authors noted that "attempts to disentangle the cancer research effort from industry merit further attention, and journals should embrace both rigorous standards of disclosure and heightened scrutiny when conflicts exist."


'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
3. Arbios Systems, Incs Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
4. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
5. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
6. Peer-Reviewed, Online Database Showcases Local, County and State Pandemic Planning
7. InstaCare Corp. Reviewing M&A Plans
8. CCF Reviews Contents of SCHIP Reauthorization Bill Legislation Places SCHIP on Solid Path
9. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
10. Multicountry review shows that Bug Buster Kits reduce head lice and social stigma
11. MaxLife Fund Corp. retains the Law firm, Anslow & Jaclin, LLP of Manalapan, N.J., to review MaxLife Fund Corp. options to be listed on the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... 2017 , ... One thing common to all types of cancer is that ... well. The money spent screening for and treating cancer in the United States is ... cancer more than in any other country that has an advanced healthcare system, sometimes ...
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and beyond the ... to better communities around the world by offering the Gensuite team and their ... for team members to become involved in a cause that is bigger than ...
(Date:1/15/2017)... IL (PRWEB) , ... January 14, 2017 , ... Wondering ... Lobster Gram Dinner delivered straight to your door for a romantic, lobster feast in ... just in time for Valentine's Day. The dinners will be featured until February ...
(Date:1/14/2017)... ... January 14, 2017 , ... AgileMinder develops innovative products and services ... Scale is now available on Apple as a fun, free emoji sticker pack for ... one of the ten color coded values on The Emoji Scale. , On ...
(Date:1/13/2017)... ... 2017 , ... KOAMTAC ®, Inc., a leading manufacturer of Bluetooth barcode ... scanner and data collector at the National Retail Federation’s Big Show (NRF17) held January ... to the market’s need for more compact and rugged devices for collecting barcode data ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... YORK , Jan. 12, 2017  Rosen Law ... filing of a class action lawsuit on behalf of ... ALXN ) from February 10, 2014 through November 9, ... recover damages for Alexion investors under the federal securities ... go to http://rosenlegal.com/cases-991.html or call Phillip ...
(Date:1/13/2017)... JAKARTA , Jan. 13, 2017 Over the last 10 ... been developing rapidly (6% – 10% yoy) and are expected to deliver ... in the region, followed by Thailand , ... , and Singapore .  A member of the ... represents almost 40% of the SEA,s economic output and the largest ...
(Date:1/13/2017)... 2017 ... Research and Markets has announced the addition ... to their offering. The disease is divided into ... are early-stage melanoma, which can be treated with surgery, and advanced ... with early-stage therapy aiming to prevent disease re-occurrence, and advanced therapies ...
Breaking Medicine Technology: